Deutsche Bank Aktiengesellschaft Reaffirms “Hold” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “hold” rating restated by analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Thursday, MarketBeat Ratings reports. They presently have a GBX 1,450 ($19.25) price objective on the stock. Deutsche Bank Aktiengesellschaft’s price target indicates a potential upside of 3.83% from the company’s previous close.

Several other brokerages have also recently issued reports on GSK. Berenberg Bank reaffirmed a “hold” rating and set a GBX 1,600 ($21.24) price objective on shares of GSK in a report on Friday, July 18th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Friday, July 18th. Finally, Shore Capital reaffirmed a “buy” rating and set a GBX 2,000 ($26.55) price target on shares of GSK in a research note on Wednesday.

GSK Stock Down 1.5%

Shares of GSK stock opened at GBX 1,396.50 ($18.54) on Thursday. GSK has a one year low of GBX 1,242.50 ($16.49) and a one year high of GBX 1,678.68 ($22.28). The company has a market cap of £56.67 billion, a P/E ratio of 22.56, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The firm has a fifty day moving average of GBX 1,434.66 and a two-hundred day moving average of GBX 1,425.41.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 ($1.00) earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insider Activity

In other news, insider Jonathan Symonds bought 1,350 shares of GSK stock in a transaction on Friday, June 20th. The shares were bought at an average cost of GBX 1,435 ($19.05) per share, for a total transaction of £19,372.50 ($25,713.43). Also, insider Wendy Becker purchased 545 shares of the stock in a transaction dated Friday, June 20th. The shares were purchased at an average price of GBX 1,435 ($19.05) per share, with a total value of £7,820.75 ($10,380.61). Insiders have purchased 1,905 shares of company stock worth $2,732,835 over the last three months. 1.61% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.